We serve FMOC-3-L-ALA(2-THIENYL)-OH CAS:130309-35-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
| Items of Analysis | Standard of Analysis | Test Results |
| Appearance | White to off-white powder | Conform |
| Purity (HPLC) | ≥98.0% | 99.48% |
| Optical Purity | ≤0.5% D-enantiomer | ND |
| TLC | ≥98.0% | ＞98.0% |
| Melting point | 165-178℃ | 169.9-175.0℃ |
| Specific Rotation[a]20D | -32o±2o (C=1 in DMF) | -32.8o |
| Clarity of solution | 0.3 gram in 2ml DMF clear solution | Conform |
| Water | ≤1.0% | 0.08% |
| Loss on drying | ≤1.0% | 0.34% |
| Conclusion | Conforms to Factory Standard | |
Contact us for information like FMOC-3-L-ALA(2-THIENYL)-OH chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Fmoc-3-Ala(2-thienyl)-OH physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,N-[(9H-Fluoren-9-ylmethoxy)carbonyl]-2-(2-thienyl)-L-alanine Use and application,(S)-N-FMOC-2-Thienylalanine technical grade,usp/ep/jp grade.
Related News: Since the listing of high-barrier generic drugs involves quickly bypassing or challenging process patents of original research products within a short period of time, API companies play an important role in the process of marketing and sales of generic drugs.2-[1-(5,6,7,8-tetrahydro-naphthalen-1-yloxy)-ethyl]-4,5-dihydro-1H-imidazole manufacturer Since the listing of high-barrier generic drugs involves quickly bypassing or challenging process patents of original research products within a short period of time, API companies play an important role in the process of marketing and sales of generic drugs.5-chloro-N-(1-methoxy-3-(4-(2-oxopyridin-1(2H)-yl)benzamido)propan-2-yl)thiophene-2-carboxamide supplier Slow business: Due to fear — and travel warnings — fewer people want to travel to China.1-(1-bromocyclopropyl)-4-(2-methyl-1,3-dioxolan-2-yl)butan-1-one vendor In an August overhaul to its drug administration law, Beijing said conditional approval could be granted to some still-under-research medicines of “predictable” clinical value for life-threatening diseases for which effective treatment is not immediately available.In an August overhaul to its drug administration law, Beijing said conditional approval could be granted to some still-under-research medicines of “predictable” clinical value for life-threatening diseases for which effective treatment is not immediately available.
